Exelixis Inc (EXEL) Q2 2019 Earnings Call Transcript
All right. Many thanks, Susan, and because of everyone for signing up for us on the decision today. Exelixis had a strong Q2 with important progress across all components of our business. We maintained a strong momentum even as we grow CABOMETYX earnings, progress our cabozantinib development program, and diversify our oncology pipeline with new brokers from exterior and inner sources.
I’ll begin today by providing a brief summary of our Q2 milestones and then convert the call over to Chris, Peter, Gisela, and PJ to review important the different parts of our business. 0.29 per share. Our Q2 results confirm that cabozantinibs best in course TKI profile can drive strong growth when confronted with competition from three different ICI centered mixtures in RCC. Second, our cabozantinib development program aggressively continues to move forwards, as we advance for ongoing pivotal trials and showcase important progress in the prostate tumor and ICI refractory non-small cell lung cancers cohorts of the COSMIC 0.21 trial.
And third, today’s announcement of an easy multi-target collaboration with Aurigene that suits our attempts to build a varied early stage pipeline. Our progress throughout Q2 highlights the company’s performance across, a lot of parts of our business throughout a powerful time for both RCC and HCC indications. Our overall strategic goals remain the same. We seek to develop revenues, manage expenses carefully, and we reinvest free cash to create a diversified business with the capacity of long-term sustainable growth. So with that, I’ll turn the call to …